International collaboration secures €1M grant to investigate new treatment target for lymphoma

international collaboration secures e1m grant to investigate new treatment target for lymphoma

Sumary of International collaboration secures €1M grant to investigate new treatment target for lymphoma:

  • An international collaboration involving researchers from Queen Mary University of London, Memorial Sloan Kettering Cancer Center (MSK), New York and Dana-Farber Cancer Institute, Boston has secured a €1M research grant from Dutch blood cancer charity, Lymph&Co, to investigate a new treatment target for lymphoma.
  • The aim of the project is to determine how targeting a protein called KDM5 kills lymphoma cells, and to identify the patient groups most likely to benefit from this type of treatment.
  • Lymphoma is a type of blood cancer that arises from white blood cells called lymphocytes.
  • Changes in the genetic code (mutations) of lymphocytes can cause them to grow uncontrollably and, as a result, these white blood cells collect in lymph nodes and other tissues, eventually giving rise to lymphoma.
  • There are two main types of lymphoma: Hodgkin’s and non-Hodgkin’s lymphoma (NHL), which comprise over 60 subtypes.
  • Combatting the effects of common lymphoma mutations Research has shown that many lymphoma patients have one or more mutations in a gene called KMT2D.
  • The KMT2D gene codes for a protein involved in controlling gene expression within cells;
  • however, mutations that stop KMT2D from functioning correctly (leading to changes in the expression of genes required for normal cell function) are the most common mutations detected in lymphoma.

Want to know more click here go to source.

From -


Site Language

By continuing to use the site, you agree to the use of cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.